• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 危重症患者插管时间对死亡率和肺部后遗症的影响:一项前瞻性队列研究。

Impact of time to intubation on mortality and pulmonary sequelae in critically ill patients with COVID-19: a prospective cohort study.

机构信息

Pulmonary Department, Hospital Universitari Arnau de Vilanova and Santa Maria, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.

Translational Research in Respiratory Medicine Group (TRRM), Lleida, Spain.

出版信息

Crit Care. 2022 Jan 10;26(1):18. doi: 10.1186/s13054-021-03882-1.

DOI:10.1186/s13054-021-03882-1
PMID:35012662
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8744383/
Abstract

QUESTION

We evaluated whether the time between first respiratory support and intubation of patients receiving invasive mechanical ventilation (IMV) due to COVID-19 was associated with mortality or pulmonary sequelae.

MATERIALS AND METHODS

Prospective cohort of critical COVID-19 patients on IMV. Patients were classified as early intubation if they were intubated within the first 48 h from the first respiratory support or delayed intubation if they were intubated later. Surviving patients were evaluated after hospital discharge.

RESULTS

We included 205 patients (140 with early IMV and 65 with delayed IMV). The median [p;p] age was 63 [56.0; 70.0] years, and 74.1% were male. The survival analysis showed a significant increase in the risk of mortality in the delayed group with an adjusted hazard ratio (HR) of 2.45 (95% CI 1.29-4.65). The continuous predictor time to IMV showed a nonlinear association with the risk of in-hospital mortality. A multivariate mortality model showed that delay of IMV was a factor associated with mortality (HR of 2.40; 95% CI 1.42-4.1). During follow-up, patients in the delayed group showed a worse DLCO (mean difference of - 10.77 (95% CI - 18.40 to - 3.15), with a greater number of affected lobes (+ 1.51 [95% CI 0.89-2.13]) and a greater TSS (+ 4.35 [95% CI 2.41-6.27]) in the chest CT scan.

CONCLUSIONS

Among critically ill patients with COVID-19 who required IMV, the delay in intubation from the first respiratory support was associated with an increase in hospital mortality and worse pulmonary sequelae during follow-up.

摘要

问题

我们评估了 COVID-19 患者因接受有创机械通气(IMV)而首次接受呼吸支持与气管插管之间的时间间隔是否与死亡率或肺部后遗症有关。

材料和方法

对接受 IMV 的严重 COVID-19 患者进行前瞻性队列研究。如果患者在首次呼吸支持后的 48 小时内插管,则将其分类为早期插管;如果患者在 48 小时后插管,则将其分类为延迟插管。存活的患者在出院后进行评估。

结果

我们纳入了 205 名患者(140 名早期 IMV 和 65 名延迟 IMV)。中位[P;P]年龄为 63 [56.0; 70.0]岁,74.1%为男性。生存分析显示,延迟组的死亡率风险显著增加,调整后的危险比(HR)为 2.45(95%CI 1.29-4.65)。连续预测变量气管插管时间与住院死亡率的风险呈非线性关系。多变量死亡率模型显示,IMV 的延迟是与死亡率相关的因素(HR 为 2.40;95%CI 1.42-4.1)。在随访期间,延迟组的患者显示出较低的 DLCO(平均差异-10.77(95%CI -18.40 至-3.15)),更多的受累肺叶(+1.51(95%CI 0.89-2.13))和更大的 TSS(+4.35(95%CI 2.41-6.27))在胸部 CT 扫描中。

结论

在需要 IMV 的 COVID-19 危重症患者中,从首次呼吸支持到气管插管的延迟与住院死亡率的增加和随访期间更严重的肺部后遗症有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d9/8751333/58f99fec63cc/13054_2021_3882_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d9/8751333/85a037be5862/13054_2021_3882_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d9/8751333/d737b03ed187/13054_2021_3882_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d9/8751333/58f99fec63cc/13054_2021_3882_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d9/8751333/85a037be5862/13054_2021_3882_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d9/8751333/d737b03ed187/13054_2021_3882_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6d9/8751333/58f99fec63cc/13054_2021_3882_Fig3_HTML.jpg

相似文献

1
Impact of time to intubation on mortality and pulmonary sequelae in critically ill patients with COVID-19: a prospective cohort study.COVID-19 危重症患者插管时间对死亡率和肺部后遗症的影响:一项前瞻性队列研究。
Crit Care. 2022 Jan 10;26(1):18. doi: 10.1186/s13054-021-03882-1.
2
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
3
Early spontaneous breathing for acute respiratory distress syndrome in individuals with COVID-19.COVID-19 相关急性呼吸窘迫综合征患者的早期自主呼吸。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD015077. doi: 10.1002/14651858.CD015077.
4
Early versus late tracheostomy in critically ill COVID-19 patients.危重症 COVID-19 患者的早期与晚期气管切开术。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD015532. doi: 10.1002/14651858.CD015532.
5
Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients.在危重症患者中,依托咪酯单次诱导剂量与其他诱导剂用于气管插管的比较。
Cochrane Database Syst Rev. 2015 Jan 8;1(1):CD010225. doi: 10.1002/14651858.CD010225.pub2.
6
Early intervention (mobilization or active exercise) for critically ill adults in the intensive care unit.对重症监护病房中的成年重症患者进行早期干预(活动或主动锻炼)。
Cochrane Database Syst Rev. 2018 Mar 27;3(3):CD010754. doi: 10.1002/14651858.CD010754.pub2.
7
The Effects of Enteral Nutrition in Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis.新冠肺炎危重症患者肠内营养的效果:系统评价和荟萃分析。
Nutrients. 2022 Mar 7;14(5):1120. doi: 10.3390/nu14051120.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease.无创通气用于治疗慢性阻塞性肺疾病急性加重所致的急性高碳酸血症性呼吸衰竭。
Cochrane Database Syst Rev. 2017 Jul 13;7(7):CD004104. doi: 10.1002/14651858.CD004104.pub4.
10
Silver-coated endotracheal tubes for prevention of ventilator-associated pneumonia in critically ill patients.用于预防重症患者呼吸机相关性肺炎的镀银气管插管
Cochrane Database Syst Rev. 2015 Aug 12;2015(8):CD009201. doi: 10.1002/14651858.CD009201.pub2.

引用本文的文献

1
High-flow nasal oxygen is the reference treatment in acute hypoxemic respiratory failure: Con.高流量鼻导管给氧是急性低氧性呼吸衰竭的参考治疗方法:反对意见。
J Intensive Med. 2025 Jan 21;5(3):230-236. doi: 10.1016/j.jointm.2024.12.005. eCollection 2025 Jul.
2
Longitudinal recovery trajectories and ventilatory modalities in COVID-19 acute respiratory distress syndrome survivors.新冠病毒病(COVID-19)急性呼吸窘迫综合征幸存者的纵向恢复轨迹及通气模式
ERJ Open Res. 2025 Apr 7;11(2). doi: 10.1183/23120541.00770-2024. eCollection 2025 Mar.
3
Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study.

本文引用的文献

1
Three to Six Months Evolution of Pulmonary Function and Radiological Features in Critical COVID-19 Patients: A Prospective Cohort.重症COVID-19患者肺功能和影像学特征的三至六个月演变:一项前瞻性队列研究
Arch Bronconeumol. 2021 Jul 27. doi: 10.1016/j.arbres.2021.07.005.
2
Three to Six Months Evolution of Pulmonary Function and Radiological Features in Critical COVID-19 Patients: A Prospective Cohort.重症 COVID-19 患者肺功能和影像学特征的三至六个月演变:一项前瞻性队列研究
Arch Bronconeumol. 2022 Apr;58:59-62. doi: 10.1016/j.arbres.2021.07.005. Epub 2021 Jul 27.
3
Noninvasive respiratory support outside the intensive care unit for acute respiratory failure related to coronavirus-19 disease: a systematic review and meta-analysis.
低剂量吸入一氧化氮治疗有自主呼吸和插管的 COVID-19 患者的影响:一项回顾性倾向评分匹配研究。
Crit Care. 2024 Oct 25;28(1):344. doi: 10.1186/s13054-024-05093-w.
4
Effect of noninvasive ventilation on mortality and clinical outcomes among patients with severe hypoxemic COVID-19 pneumonia after high-flow nasal oxygen failure: a multicenter retrospective French cohort with propensity score analysis.高流量鼻氧失败后严重低氧血症 COVID-19 肺炎患者无创通气对死亡率和临床结局的影响:一项采用倾向性评分分析的多中心回顾性法国队列研究。
Respir Res. 2024 Jul 15;25(1):279. doi: 10.1186/s12931-024-02873-4.
5
A comparison study of temporal trends of SARS-CoV2 RNAemia and biomarkers to predict success and failure of high flow oxygen therapy among patients with moderate to severe COVID-19.一项关于 SARS-CoV2 血症 RNA 与生物标志物的时间趋势比较研究,以预测中重度 COVID-19 患者高流量氧疗的成功与失败。
PLoS One. 2024 Jul 10;19(7):e0305077. doi: 10.1371/journal.pone.0305077. eCollection 2024.
6
Use of a gas-operated ventilator as a noninvasive bridging respiratory therapy in critically Ill COVID-19 patients in a middle-income country.在一个中等收入国家,使用气动呼吸机作为重症新冠肺炎患者的无创过渡性呼吸治疗手段。
Intern Emerg Med. 2025 Mar;20(2):543-551. doi: 10.1007/s11739-024-03681-w. Epub 2024 Jun 28.
7
Effect of immediate initiation of invasive ventilation on mortality in acute hypoxemic respiratory failure: a target trial emulation.即刻启动有创通气对急性低氧性呼吸衰竭患者死亡率的影响:一项模拟目标试验。
Crit Care. 2024 May 10;28(1):157. doi: 10.1186/s13054-024-04926-y.
8
The Respiratory Mechanics of COVID-19 Acute Respiratory Distress Syndrome-Lessons Learned?新型冠状病毒肺炎急性呼吸窘迫综合征的呼吸力学——吸取的教训?
J Clin Med. 2024 Mar 22;13(7):1833. doi: 10.3390/jcm13071833.
9
Point-of-care ultrasound use in COVID-19: a narrative review.即时超声在2019冠状病毒病中的应用:一项叙述性综述。
Ann Transl Med. 2024 Feb 1;12(1):13. doi: 10.21037/atm-23-1403. Epub 2023 Jul 13.
10
Advanced Respiratory Support Days as a Novel Marker of Mortality in COVID-19 Acute Respiratory Distress Syndrome Requiring Extracorporeal Membrane Oxygenation.高级呼吸支持天数是 COVID-19 急性呼吸窘迫综合征需要体外膜肺氧合患者的死亡率的新标志物。
ASAIO J. 2024 May 1;70(5):427-435. doi: 10.1097/MAT.0000000000002119. Epub 2024 Jan 31.
重症监护病房外针对冠状病毒病19相关急性呼吸衰竭的无创呼吸支持:一项系统评价和荟萃分析
Crit Care. 2021 Jul 30;25(1):268. doi: 10.1186/s13054-021-03697-0.
4
Intubation timing as determinant of outcome in patients with acute respiratory distress syndrome by SARS-CoV-2 infection.插管时机对新型冠状病毒 2 型感染所致急性呼吸窘迫综合征患者预后的影响
J Crit Care. 2021 Oct;65:164-169. doi: 10.1016/j.jcrc.2021.06.008. Epub 2021 Jun 17.
5
Implications of early respiratory support strategies on disease progression in critical COVID-19: a matched subanalysis of the prospective RISC-19-ICU cohort.早期呼吸支持策略对危重新冠肺炎疾病进展的影响:前瞻性 RISC-19-ICU 队列的匹配亚组分析。
Crit Care. 2021 May 25;25(1):175. doi: 10.1186/s13054-021-03580-y.
6
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study.COVID-19 相关住院患者的 3 个月、6 个月、9 个月和 12 个月呼吸结局:一项前瞻性研究。
Lancet Respir Med. 2021 Jul;9(7):747-754. doi: 10.1016/S2213-2600(21)00174-0. Epub 2021 May 5.
7
Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort.新冠肺炎危重症幸存者的肺功能和影像学特征:一项为期 3 个月的前瞻性队列研究。
Chest. 2021 Jul;160(1):187-198. doi: 10.1016/j.chest.2021.02.062. Epub 2021 Mar 4.
8
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.新冠肺炎出院患者 6 个月的后果:一项队列研究。
Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.
9
Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?法国重症监护病房收治的危重症新冠肺炎患者第一波与第二波情况比较:第二波期间预后无改善?
Crit Care. 2021 Jan 4;25(1):3. doi: 10.1186/s13054-020-03449-6.
10
Reply: Optimal Respiratory Assistance Strategy for Patients with COVID-19.回复:新型冠状病毒肺炎患者的最佳呼吸支持策略
Ann Am Thorac Soc. 2021 May;18(5):917-918. doi: 10.1513/AnnalsATS.202012-1501LE.